Key result
The use of alloyed CdZnSeS/ZnS quantum dots allowed the determination of doxorubicin in the presence of bortezomib in plasma with a detection limit of 0.08 μM and quantification limit of 0.24 μM.
Why the study?
Because doxorubicin is often used in combination chemotherapy with bortezomib, monitoring its plasma concentration is important for increasing chemotherapy effectiveness and reducing side effect risks.
A new procedure using quantum dots allows for the sensitive determination of doxorubicin in the presence of bortezomib in blood plasma, which could aid in monitoring combination chemotherapy.
May aid doxorubicin monitoring during bortezomib co-therapy; leaves open clinical translation beyond animal plasma.
A procedure for determining doxorubicin in the presence of bortezomib in model aqueous solutions and blood plasma is developed based on the fluorescence quenching of CdZnSeS/ZnS and AgInS/ZnS quantum dots. Since doxorubicin is often used in combination chemotherapy with bortezomib, monitoring its plasma concentration is important for increasing the effectiveness of chemotherapy and reducing the risk of side effects. The sensitivity of doxorubicin determination in the presence of bortezomib (0.3 μM) is compared using quantum dots with different surface ligands. A trend toward decreased fluorescence quenching efficiency of quantum dots by doxorubicin in the presence of bortezomib is demonstrated. The use of alloyed CdZnSeS/ZnS quantum dots stabilized with 3-mercaptropropionic acid for the determination of doxorubicin in the presence of bortezomib in plasma is demonstrated, with a detection limit of 0.08 μM and a quantification limit of 0.24 μM.
No takes yet. Share an insight, caveat, or question.
Meshcheryakova et al. (2026) studied this question. Fluorescence quenching of CdZnSeS/ZnS and AgInS/ZnS quantum dots was evaluated on Detection limit and quantification limit of doxorubicin in the presence of bortezomib in plasma. The use of alloyed CdZnSeS/ZnS quantum dots allowed the determination of doxorubicin in the presence of bortezomib in plasma with a detection limit of 0.08 μM and quantification limit of 0.24 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: